Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Vanderbilt University Spasticity Management Program Evaluation Plan

This study has been completed.
Information provided by:
Vanderbilt University Identifier:
First received: September 13, 2005
Last updated: August 17, 2007
Last verified: August 2007

People with severe developmental disabilities frequently have comorbidities that make providing care to them more difficult. Spasticity is one such comorbidity. It produces increased muscle tone that can cause stiffness in joints and bodily contortions that can interfere with all of the major types of care provided to participants. Typically, care areas include splinting, hygiene, dressing, transfers, positioning, ambulation, and engaging in other functional activities. Moreover, persons with spasticity often experience pain.

Typically, spasticity is managed by health care providers using a combination of the following therapies:

  • Physical / occupational therapy (PT / OT)
  • Oral medication
  • Botox injections
  • Intrathecal baclofen administered by the Medtronic SyncroMed pump (ITB)
  • Orthopedic / neurological surgery

Condition Intervention Phase
Drug: Botulinum Toxin Type A
Drug: Intrathecal baclofen administered by the Medtronic SyncroMed(TM) pump (ITB)
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Vanderbilt University Spasticity Management Program Evaluation Plan

Further study details as provided by Vanderbilt University:

Primary Outcome Measures:
  • Total time (in seconds) spent by caregivers to complete a defined care area task at one year followup.
  • Categorical rating by blinded, independent reviewer of baseline and one-year care area task videos.

Secondary Outcome Measures:
  • Range of motion score for each care area goal, assigned by physical therapist and compared at baseline vs. one-year followup.
  • Differences in the number of hospital admissions 12 months pre- and 12 months post-program.
  • Differences in costs associated with caregiving 12 months pre- and 12 months post-treatment.
  • Difference in Physician's global assessment of spasticity at baseline and one-year followup.

Estimated Enrollment: 20
Study Start Date: August 2002
Estimated Study Completion Date: February 2006
Detailed Description:
As individuals are identified as appropriate participants for the Program and consent is obtained, the care team for each person, consisting of both medical and caregiver staff, will define up to three specific care area goals and related tasks for treatment. A comprehensive spasticity management program will then be developed for the individual. Clinical and outcome assessments at baseline and at follow-up will include measures of range of motion, global spasticity according to a modified Ashworth scale, and the time and number of staff required for the task. In addition, video will be obtained of caregivers performing each participant's care area tasks at baseline and follow-up to allow an independent external reviewer to judge task difficulty. Treatment will be provided as outlined by the spasticity management plan. Follow-up evaluations will be conducted when the participant is at least one year from their initial Botulinum injection, or are one year post-implant for ITB participants. When the participant is exited from the study, Survey Physician will be asked to rate the overall impact of the Program on each of the individual's care area tasks.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult with spasticity residing at Clover Bottom Developmental Center in Nashville, Tennessee.
  • Spasticity must interfere with daily functioning.
  • Care team must be able to identify at least one treatment goal for the potential participant.

Exclusion Criteria:

  • Family or guardian is unwilling to provide written informed consent.
  • Spasticity does not interfere with patient's day-to-day care.
  • Staff who provide daily care are unable to identify a clear treatment goal.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00179114

United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37212
Sponsors and Collaborators
Vanderbilt University
Principal Investigator: David Charles, MD Vanderbilt University Department of Neurology
  More Information Identifier: NCT00179114     History of Changes
Other Study ID Numbers: SMPEP-9.1
Study First Received: September 13, 2005
Last Updated: August 17, 2007

Keywords provided by Vanderbilt University:
Developmental Disabilities
Intrathecal baclofen (ITB)
Botulinum Toxin Type A (Botox)

Additional relevant MeSH terms:
Muscle Spasticity
Muscular Diseases
Musculoskeletal Diseases
Muscle Hypertonia
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Botulinum Toxins, Type A
Botulinum Toxins
Neuromuscular Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Acetylcholine Release Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents processed this record on April 28, 2017